Download PDF
Semin Thromb Hemost 2019; 45(01): 050-060
DOI: 10.1055/s-0038-1657782
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Inherited Thrombophilia and Pregnancy Complications: Should We Test?

Deepa R.J. Arachchillage
1   Department of Haematology, Imperial College Healthcare NHS Trust and Imperial College London, Hammersmith Hospital, London, United Kingdom
2   Department of Haematology, Royal Brompton Hospital, London, United Kingdom
,
Mike Makris
3   Sheffield Haemophilia and Thrombosis Centre, Royal Hallamshire Hospital, Sheffield, United Kingdom
4   Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, United Kingdom
› Author Affiliations
Further Information

Publication History

Publication Date:
04 June 2018 (online)

    Permissions and Reprints

Corrected by:

Erratum: Inherited Thrombophilia and Pregnancy Complications: Should We Test?Semin Thromb Hemost eFirst
DOI: 10.1055/s-0039-1678545

Abstract

Recurrent miscarriages and pregnancy-related complications cause significant stress to couples looking for successful pregnancy outcome as well as to health care professionals. There is conflicting evidence with respect to the presence and the strength of associations between inherited thrombophilia and these complications. A complete thrombophilia screen is expensive, and no proven effective treatment for women with recurrent miscarriage and inherited thrombophilia is currently available. Based on the concept of microvascular thrombosis of the placenta, women with recurrent miscarriage and placenta-related complications frequently get treated with antithrombotic therapy. In this narrative review, the authors explore the evolving understanding and evidence of inherited thrombophilia in recurrent miscarriages and other pregnancy complications, and whether antithrombotic treatment would modify pregnancy outcome in women with inherited thrombophilia. Finally, they provide some personal recommendations based on available evidence for clinical practice. In summary, inherited thrombophilia testing is not required outside a clinical trial for women with recurrent pregnancy losses or late pregnancy complications. The presence of thrombophilia markers does not generally indicate additional therapy during pregnancy, even if a heritable thrombophilic defect is found in women with recurrent miscarriages or late pregnancy complications.

Keywords

pregnancy - recurrent miscarriage - thrombophilia - low molecular weight heparin - aspirin

Author Cpntributions

D. R. J. Arachchillage performed the literature search and wrote the first draft, and M. Makris reviewed the manuscript. Both authors approved the final manuscript.


 

  • References

  • 1 Wang X, Chen C, Wang L, Chen D, Guang W, French J. Conception, early pregnancy loss, and time to clinical pregnancy: a population-based prospective study. Fertil Steril 2003; 79 (03) 577-584
    CrossrefPubMedGoogle Scholar
  • 2 Regan L, Rai R. Epidemiology and the medical causes of miscarriage. Best Pract Res Clin Obstet Gynaecol 2000; 14 (05) 839-854
    CrossrefPubMedGoogle Scholar
  • 3 Regan L, Backos M, Rai R. The Investigation and Treatment of Couples with Recurrent First-trimester and Second-trimester Miscarriage. RCOG Green-top Guideline No. 17. April 2010. http://www.rcog.org.uk . Accessed October 27, 2017
    PubMedGoogle Scholar
  • 4 Farquharson RG, Jauniaux E, Exalto N. ; ESHRE Special Interest Group for Early Pregnancy (SIGEP). Updated and revised nomenclature for description of early pregnancy events. Hum Reprod 2005; 20 (11) 3008-3011
    CrossrefPubMedGoogle Scholar
  • 5 Jauniaux E, Farquharson RG, Christiansen OB, Exalto N. Evidence-based guidelines for the investigation and medical treatment of recurrent miscarriage. Hum Reprod 2006; 21 (09) 2216-2222
    CrossrefPubMedGoogle Scholar
  • 6 American College of Obstetricians and Gynecologists Women's Health Care Physicians. ACOG Practice Bulletin No. 138: inherited thrombophilias in pregnancy. Obstet Gynecol 2013; 122 (03) 706-717
    CrossrefPubMedGoogle Scholar
  • 7 Poland BJ, Miller JR, Jones DC, Trimble BK. Reproductive counseling in patients who have had a spontaneous abortion. Am J Obstet Gynecol 1977; 127 (07) 685-691
    CrossrefPubMedGoogle Scholar
  • 8 Craig M, Tata P, Regan L. Psychiatric morbidity among patients with recurrent miscarriage. J Psychosom Obstet Gynaecol 2002; 23 (03) 157-164
    CrossrefPubMedGoogle Scholar
  • 9 Bennett SA, Bagot CN, Arya R. Pregnancy loss and thrombophilia: the elusive link. Br J Haematol 2012; 157 (05) 529-542
    CrossrefPubMedGoogle Scholar
  • 10 Stephenson MD, Awartani KA, Robinson WP. Cytogenetic analysis of miscarriages from couples with recurrent miscarriage: a case-control study. Hum Reprod 2002; 17 (02) 446-451
    CrossrefPubMedGoogle Scholar
  • 11 Alijotas-Reig J, Garrido-Gimenez C. Current concepts and new trends in the diagnosis and management of recurrent miscarriage. Obstet Gynecol Surv 2013; 68 (06) 445-466
    CrossrefPubMedGoogle Scholar
  • 12 Practice Committee of the American Society for Reproductive Medicine. Evaluation and treatment of recurrent pregnancy loss: a committee opinion. Fertil Steril 2012; 98 (05) 1103-1111
    CrossrefPubMedGoogle Scholar
  • 13 Nybo Andersen AM, Wohlfahrt J, Christens P, Olsen J, Melbye M. Maternal age and fetal loss: population based register linkage study. BMJ 2000; 320 (7251): 1708-1712
    CrossrefPubMedGoogle Scholar
  • 14 Horne AW, Alexander CI. Recurrent miscarriage. J Fam Plann Reprod Health Care 2005; 31 (02) 103-107
    CrossrefPubMedGoogle Scholar
  • 15 Rai R, Regan L. Recurrent miscarriage. Lancet 2006; 368 (9535): 601-611
    CrossrefPubMedGoogle Scholar
  • 16 Porter TF, Scott JR. Evidence-based care of recurrent miscarriage. Best Pract Res Clin Obstet Gynaecol 2005; 19 (01) 85-101
    CrossrefPubMedGoogle Scholar
  • 17 Stephenson MD. Frequency of factors associated with habitual abortion in 197 couples. Fertil Steril 1996; 66 (01) 24-29
    CrossrefPubMedGoogle Scholar
  • 18 Cohn DM, Goddijn M, Middeldorp S, Korevaar JC, Dawood F, Farquharson RG. Recurrent miscarriage and antiphospholipid antibodies: prognosis of subsequent pregnancy. J Thromb Haemost 2010; 8 (10) 2208-2213
    CrossrefPubMedGoogle Scholar
  • 19 Branch DW, Silver R, Pierangeli S, van Leeuwen I, Harris EN. Antiphospholipid antibodies other than lupus anticoagulant and anticardiolipin antibodies in women with recurrent pregnancy loss, fertile controls, and antiphospholipid syndrome. Obstet Gynecol 1997; 89 (04) 549-555
    CrossrefPubMedGoogle Scholar
  • 20 Nodler J, Moolamalla SR, Ledger EM, Nuwayhid BS, Mulla ZD. Elevated antiphospholipid antibody titers and adverse pregnancy outcomes: analysis of a population-based hospital dataset. BMC Pregnancy Childbirth 2009; 9: 11
    CrossrefPubMedGoogle Scholar
  • 21 Out HJ, Bruinse HW, Christiaens GC. , et al. A prospective, controlled multicenter study on the obstetric risks of pregnant women with antiphospholipid antibodies. Am J Obstet Gynecol 1992; 167 (01) 26-32
    CrossrefPubMedGoogle Scholar
  • 22 Rai RS, Regan L, Clifford K. , et al. Antiphospholipid antibodies and beta 2-glycoprotein-I in 500 women with recurrent miscarriage: results of a comprehensive screening approach. Hum Reprod 1995; 10 (08) 2001-2005
    CrossrefPubMedGoogle Scholar
  • 23 Robertson L, Wu O, Langhorne P. , et al; Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) Study. Thrombophilia in pregnancy: a systematic review. Br J Haematol 2006; 132 (02) 171-196
    CrossrefPubMedGoogle Scholar
  • 24 Rey E, Kahn SR, David M, Shrier I. Thrombophilic disorders and fetal loss: a meta-analysis. Lancet 2003; 361 (9361): 901-908
    CrossrefPubMedGoogle Scholar
  • 25 Greer IA. Thrombophilia: implications for pregnancy outcome. Thromb Res 2003; 109 (2-3): 73-81
    CrossrefPubMedGoogle Scholar
  • 26 Sood R, Kalloway S, Mast AE, Hillard CJ, Weiler H. Fetomaternal cross talk in the placental vascular bed: control of coagulation by trophoblast cells. Blood 2006; 107 (08) 3173-3180
    CrossrefPubMedGoogle Scholar
  • 27 Pabinger I. Thrombophilia and its impact on pregnancy. Hamostaseologie 2008; 28 (03) 130-134
    Article in Thieme ConnectPubMedGoogle Scholar
  • 28 An J, Waitara MS, Bordas M. , et al. Heparin rescues factor V Leiden-associated placental failure independent of anticoagulation in a murine high-risk pregnancy model. Blood 2013; 121 (11) 2127-2134
    CrossrefPubMedGoogle Scholar
  • 29 Leaf RK, Connors JM. The role of anticoagulants in the prevention of pregnancy complications. Clin Appl Thromb Hemost 2017; 23 (02) 116-123
    CrossrefPubMedGoogle Scholar
  • 30 Lanir N, Aharon A, Brenner B. Procoagulant and anticoagulant mechanisms in human placenta. Semin Thromb Hemost 2003; 29 (02) 175-184
    Article in Thieme ConnectPubMedGoogle Scholar
  • 31 Roberts D, Schwartz RS. Clotting and hemorrhage in the placenta--a delicate balance. N Engl J Med 2002; 347 (01) 57-59
    CrossrefPubMedGoogle Scholar
  • 32 Rodger MA, Hague WM, Kingdom J. , et al; TIPPS Investigators. Antepartum dalteparin versus no antepartum dalteparin for the prevention of pregnancy complications in pregnant women with thrombophilia (TIPPS): a multinational open-label randomised trial. Lancet 2014; 384 (9955): 1673-1683
    CrossrefPubMedGoogle Scholar
  • 33 Greer IA, Nelson-Piercy C. Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. Blood 2005; 106 (02) 401-407
    CrossrefPubMedGoogle Scholar
  • 34 de Jong PG, Goddijn M, Middeldorp S. Antithrombotic therapy for pregnancy loss. Hum Reprod Update 2013; 19 (06) 656-673
    CrossrefPubMedGoogle Scholar
  • 35 Rodger MA, Betancourt MT, Clark P. , et al. The association of factor V Leiden and prothrombin gene mutation and placenta-mediated pregnancy complications: a systematic review and meta-analysis of prospective cohort studies. PLoS Med 2010; 7 (06) e1000292
    CrossrefPubMedGoogle Scholar
  • 36 Duffett L, Rodger M. LMWH to prevent placenta-mediated pregnancy complications: an update. Br J Haematol 2015; 168 (05) 619-638
    CrossrefPubMedGoogle Scholar
  • 37 Greer IA, Brenner B, Gris JC. Antithrombotic treatment for pregnancy complications: which path for the journey to precision medicine?. Br J Haematol 2014; 165 (05) 585-599
    CrossrefPubMedGoogle Scholar
  • 38 van Rijn BB, Hoeks LB, Bots ML, Franx A, Bruinse HW. Outcomes of subsequent pregnancy after first pregnancy with early-onset preeclampsia. Am J Obstet Gynecol 2006; 195 (03) 723-728
    CrossrefPubMedGoogle Scholar
  • 39 Sibai BM, Mercer B, Sarinoglu C. Severe preeclampsia in the second trimester: recurrence risk and long-term prognosis. Am J Obstet Gynecol 1991; 165 (5 Pt 1): 1408-1412
    CrossrefPubMedGoogle Scholar
  • 40 Hnat MD, Sibai BM, Caritis S. , et al; National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine-Units. Perinatal outcome in women with recurrent preeclampsia compared with women who develop preeclampsia as nulliparas. Am J Obstet Gynecol 2002; 186 (03) 422-426
    CrossrefPubMedGoogle Scholar
  • 41 Alfirevic Z, Roberts D, Martlew V. How strong is the association between maternal thrombophilia and adverse pregnancy outcome? A systematic review. Eur J Obstet Gynecol Reprod Biol 2002; 101 (01) 6-14
    CrossrefPubMedGoogle Scholar
  • 42 Lykke JA, Bare LA, Olsen J. , et al. Thrombophilias and adverse pregnancy outcomes: results from the Danish National Birth Cohort. J Thromb Haemost 2012; 10 (07) 1320-1325
    CrossrefPubMedGoogle Scholar
  • 43 Rodger MA, Walker MC, Smith GN. , et al. Is thrombophilia associated with placenta-mediated pregnancy complications? A prospective cohort study. J Thromb Haemost 2014; 12 (04) 469-478
    CrossrefPubMedGoogle Scholar
  • 44 Coulam CB, Jeyendran RS, Fishel LA, Roussev R. Multiple thrombophilic gene mutations are risk factors for implantation failure. Reprod Biomed Online 2006; 12 (03) 322-327
    CrossrefPubMedGoogle Scholar
  • 45 Grandone E, Colaizzo D, Lo Bue A, Checola MG, Cittadini E, Margaglione M. Inherited thrombophilia and in vitro fertilization implantation failure. Fertil Steril 2001; 76 (01) 201-202
    CrossrefPubMedGoogle Scholar
  • 46 Qublan HS, Eid SS, Ababneh HA. , et al. Acquired and inherited thrombophilia: implication in recurrent IVF and embryo transfer failure. Hum Reprod 2006; 21 (10) 2694-2698
    CrossrefPubMedGoogle Scholar
  • 47 Simur A, Ozdemir S, Acar H. , et al. Repeated in vitro fertilization failure and its relation with thrombophilia. Gynecol Obstet Invest 2009; 67 (02) 109-112
    CrossrefPubMedGoogle Scholar
  • 48 Martinelli I, Taioli E, Ragni G. , et al. Embryo implantation after assisted reproductive procedures and maternal thrombophilia. Haematologica 2003; 88 (07) 789-793
    PubMedGoogle Scholar
  • 49 Steinvil A, Raz R, Berliner S. , et al. Association of common thrombophilias and antiphospholipid antibodies with success rate of in vitro fertilisation. Thromb Haemost 2012; 108 (06) 1192-1197
    Article in Thieme ConnectPubMedGoogle Scholar
  • 50 Geva E, Amit A, Lerner-Geva L, Azem F, Yovel I, Lessing JB. Autoimmune disorders: another possible cause for in-vitro fertilization and embryo transfer failure. Hum Reprod 1995; 10 (10) 2560-2563
    CrossrefPubMedGoogle Scholar
  • 51 Kutteh WH, Yetman DL, Chantilis SJ, Crain J. Effect of antiphospholipid antibodies in women undergoing in-vitro fertilization: role of heparin and aspirin. Hum Reprod 1997; 12 (06) 1171-1175
    CrossrefPubMedGoogle Scholar
  • 52 Stern C, Chamley L, Norris H, Hale L, Baker HW. A randomized, double-blind, placebo-controlled trial of heparin and aspirin for women with in vitro fertilization implantation failure and antiphospholipid or antinuclear antibodies. Fertil Steril 2003; 80 (02) 376-383
    CrossrefPubMedGoogle Scholar
  • 53 Sher G, Feinman M, Zouves C. , et al. High fecundity rates following in-vitro fertilization and embryo transfer in antiphospholipid antibody seropositive women treated with heparin and aspirin. Hum Reprod 1994; 9 (12) 2278-2283
    CrossrefPubMedGoogle Scholar
  • 54 Qublan H, Amarin Z, Dabbas M. , et al. Low-molecular-weight heparin in the treatment of recurrent IVF-ET failure and thrombophilia: a prospective randomized placebo-controlled trial. Hum Fertil (Camb) 2008; 11 (04) 246-253
    CrossrefPubMedGoogle Scholar
  • 55 Kaandorp SP, Goddijn M, van der Post JA. , et al. Aspirin plus heparin or aspirin alone in women with recurrent miscarriage. N Engl J Med 2010; 362 (17) 1586-1596
    CrossrefPubMedGoogle Scholar
  • 56 Clark P, Walker ID, Langhorne P. , et al; Scottish Pregnancy Intervention Study (SPIN) collaborators. SPIN (Scottish Pregnancy Intervention) study: a multicenter, randomized controlled trial of low-molecular-weight heparin and low-dose aspirin in women with recurrent miscarriage. Blood 2010; 115 (21) 4162-4167
    CrossrefPubMedGoogle Scholar
  • 57 Visser J, Ulander VM, Helmerhorst FM. , et al. Thromboprophylaxis for recurrent miscarriage in women with or without thrombophilia. HABENOX: a randomised multicentre trial. Thromb Haemost 2011; 105 (02) 295-301
    Article in Thieme ConnectPubMedGoogle Scholar
  • 58 de Jong PG, Kaandorp S, Di Nisio M, Goddijn M, Middeldorp S. Aspirin and/or heparin for women with unexplained recurrent miscarriage with or without inherited thrombophilia. Cochrane Database Syst Rev 2014; 7 (07) CD004734
    PubMedGoogle Scholar
  • 59 Skeith L, Carrier M, Kaaja R. , et al. A meta-analysis of low-molecular-weight heparin to prevent pregnancy loss in women with inherited thrombophilia. Blood 2016; 127 (13) 1650-1655
    CrossrefPubMedGoogle Scholar
  • 60 Martinelli I, Ruggenenti P, Cetin I. , et al; HAPPY Study Group. Heparin in pregnant women with previous placenta-mediated pregnancy complications: a prospective, randomized, multicenter, controlled clinical trial. Blood 2012; 119 (14) 3269-3275
    CrossrefPubMedGoogle Scholar
  • 61 Rodger MA, Carrier M, Le Gal G. , et al; Low-Molecular-Weight Heparin for Placenta-Mediated Pregnancy Complications Study Group. Meta-analysis of low-molecular-weight heparin to prevent recurrent placenta-mediated pregnancy complications. Blood 2014; 123 (06) 822-828
    CrossrefPubMedGoogle Scholar
  • 62 Askie LM, Duley L, Henderson-Smart DJ, Stewart LA. ; PARIS Collaborative Group. Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data. Lancet 2007; 369 (9575): 1791-1798
    CrossrefPubMedGoogle Scholar
  • 63 Rodger MA, Gris JC, de Vries JIP. , et al; Low-Molecular-Weight Heparin for Placenta-Mediated Pregnancy Complications Study Group. Low-molecular-weight heparin and recurrent placenta-mediated pregnancy complications: a meta-analysis of individual patient data from randomised controlled trials. Lancet 2016; 388 (10060): 2629-2641
    CrossrefPubMedGoogle Scholar
  • 64 Gelbaya TA, Kyrgiou M, Li TC, Stern C, Nardo LG. Low-dose aspirin for in vitro fertilization: a systematic review and meta-analysis. Hum Reprod Update 2007; 13 (04) 357-364
    CrossrefPubMedGoogle Scholar
  • 65 Seshadri S, Sunkara SK, Khalaf Y, El-Toukhy T, Hamoda H. Effect of heparin on the outcome of IVF treatment: a systematic review and meta-analysis. Reprod Biomed Online 2012; 25 (06) 572-584
    CrossrefPubMedGoogle Scholar
  • 66 Perminova SG, Yavorovskaya K, Okhtyrskaya T, Shurshalina AV. The role of thrombophilia in IVF implantation failure. J Reprod Med Endocrinol. 2010; 7: 383
    PubMedGoogle Scholar
  • 67 Dentali F, Ageno W, Rezoagli E. , et al. Low-dose aspirin for in vitro fertilization or intracytoplasmic sperm injection: a systematic review and a meta-analysis of the literature. J Thromb Haemost 2012; 10 (10) 2075-2085
    CrossrefPubMedGoogle Scholar
  • 68 Bates SM, Greer IA, Middeldorp S. , et al. VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2, Suppl): 691-736
    CrossrefPubMedGoogle Scholar
  • 69 Zegers-Hochschild F, Adamson GD, de Mouzon J. , et al; International Committee for Monitoring Assisted Reproductive Technology; World Health Organization. The International Committee for Monitoring Assisted Reproductive Technology (ICMART) and the World Health Organization (WHO) Revised Glossary on ART Terminology, 2009. Hum Reprod 2009; 24 (11) 2683-2687
    CrossrefPubMedGoogle Scholar
  • 70 de Jong PG, Quenby S, Bloemenkamp KW. , et al. ALIFE2 study: low-molecular-weight heparin for women with recurrent miscarriage and inherited thrombophilia--study protocol for a randomized controlled trial. Trials 2015; 16: 208
    CrossrefPubMedGoogle Scholar
  • 71 National Institute for Health and Clinical Excellence. Ectopic pregnancy and miscarriage: diagnosis and initial management in early pregnancy of ectopic pregnancy and miscarriage. NICE Clinical Guideline 154. Manchester, UK: NICE; 2012. http://www.nice.org.uk/guidance/cg154/resources/guidance . Accessed October 27, 2017
    PubMedGoogle Scholar
  • 72 Lausman A, Kingdom J. ; MATERNAL FETAL MEDICINE COMMITTEE. Intrauterine growth restriction: screening, diagnosis, and management. J Obstet Gynaecol Can 2013; 35 (08) 741-748
    CrossrefPubMedGoogle Scholar
  • 73 Magee LA, Pels A, Helewa M, Rey E, von Dadelszen P. ; SOGC Hypertension Guideline Committee. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy: executive summary. J Obstet Gynaecol Can 2014; 36 (07) 575-576
    PubMedGoogle Scholar
  • 74 Confidential Enquiry into Maternal and Child Health(CEMACH). Perinatal Mortality 2007. London, UK: CEMACH; 2009. http://www.cmace.org.uk . Accessed on October 27, 2017
    PubMedGoogle Scholar
  • 75 Thornhill AR, deDie-Smulders CE, Geraedts JP. , et al; ESHRE PGD Consortium. ESHRE PGD Consortium ‘Best practice guidelines for clinical preimplantation genetic diagnosis (PGD) and preimplantation genetic screening (PGS).’. Hum Reprod 2005; 20 (01) 35-48
    CrossrefPubMedGoogle Scholar
  • 76 Azem F, Many A, Ben Ami I. , et al. Increased rates of thrombophilia in women with repeated IVF failures. Hum Reprod 2004; 19 (02) 368-370
    CrossrefPubMedGoogle Scholar
  • 77 Bellver J, Soares SR, Alvarez C. , et al. The role of thrombophilia and thyroid autoimmunity in unexplained infertility, implantation failure and recurrent spontaneous abortion. Hum Reprod 2008; 23 (02) 278-284
    PubMedGoogle Scholar
  • 78 Gris JC, Mercier E, Quéré I. , et al. Low-molecular-weight heparin versus low-dose aspirin in women with one fetal loss and a constitutional thrombophilic disorder. Blood 2004; 103 (10) 3695-3699
    CrossrefPubMedGoogle Scholar
  • 79 Laskin CA, Spitzer KA, Clark CA. , et al. Low molecular weight heparin and aspirin for recurrent pregnancy loss: results from the randomized, controlled HepASA Trial. J Rheumatol 2009; 36 (02) 279-287
    CrossrefPubMedGoogle Scholar
  • 80 Schleussner E, Kamin G, Seliger G. , et al; ETHIG II group. Low-molecular-weight heparin for women with unexplained recurrent pregnancy loss: a multicenter trial with a minimization randomization scheme. Ann Intern Med 2015; 162 (09) 601-609
    CrossrefPubMedGoogle Scholar